Welcome!

News Feed Item

Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy

HERSHEY, Pa. and ROCKVILLE, Md., April 24, 2013 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Hershey, PA), a leading developer of novel allergy immunotherapies, announced the preliminary results of a Phase I Study to treat individuals with an allergy to Japanese red cedar ("JRC").  The Company is pleased to report that the immunotherapeutic vaccine, JRC-LAMP-vax™, appears to have met all of its primary safety end points.  In addition, preliminary allergic marker results indicate a favorable trend in resolving the allergy.

Within the three subject sub-groups, (24 total patients) there were no reports of any Severe Adverse Events (SAE).  A small number of mild adverse events were reported in about 10% of the vaccinations, generally related to soreness associated with the intra-muscular injection.  The safety results are consistent with other clinical studies that have incorporated LAMP, which also showed the vaccine to be safe and well tolerated.  In addition to monitoring vaccine safety, subjects were also evaluated for immunological markers of allergy including circulating IgE, immunoglobulin G (IgG) and skin test reactivity. 

At the 2013 BIO International Convention, the CEO of Immunomic Therapeutics, Dr. William Hearl, presented the preliminary data for cedar specific IgE and for skin test reactivity.  All patients had stable IgE levels including those patients who entered the study as non-allergic to JRC.  This observation indicates that the vaccine does not induce a new IgE antibody response in either naive or allergic subjects.

Skin testing is perhaps the oldest and most reliable form of allergy testing.  Skin testing has been performed for 100 years and continues to be the test of choice for the diagnosis of allergic disease.  A number of the subjects, both skin test positive and skin test negative at the start of the trial, were found to be skin test negative at the end of the study: 5 of 6 converted from positive to negative for whole JRC extract and all subjects were negative for the specific cedar allergen Cry J2.  In addition, all skin test negative subjects (5) remained skin test negative at the end of the Phase I study.

"Immunomic Therapeutics, Inc., is proud to present these promising results for our first in human Phase I study.  While we are quite excited about the initial skin test results it is important to note that this is a very small number of subjects and we have no indication that the treatment would alleviate the subjects' rhinitis upon exposure to cedar pollen.  Nevertheless, the skin test results are extraordinary in that reversal of a positive result within 132 days of treatment is not usually observed with traditional immunotherapy which may last years and require a 100 or more shots.  To have seen that result within the course of this study gives us – and everyone with an allergy – hope that a solution may be on the horizon."

The Company is planning to continue collecting data for about the next 30 days and will have a more complete report available later this year.  ITI is also planning on initiating a Phase II study of JRC-LAMP-vax later this year and following that in 2014 with our first food allergy immunotherapy for peanut allergy, ARA-LAMP-vax. 

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company with lab facilities in Rockville, MD and process-development plant in Hershey, PA.  ITI is developing next generation vaccines based on the patented LAMP Technology. Our LAMP-vax vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy, cancer and infectious diseases.  For more information about ITI and LAMP Technology please visit www.immunomix.com

CONTACT:

Dr. Bill Hearl, President / CEO

Phone:  1-717-327-1919

[email protected]

Immunomic Therapeutics, Inc.

1214 Research Blvd, Suite 201

Hershey, PA 17036

E-mail:  [email protected]

Web: www.immunomix.com

SOURCE Immunomic Therapeutics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform. In his session at @ThingsExpo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and shared the must-have mindsets for removing complexity from the develop...
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business. Though, IoT is far more complex than most firms expected with a majority of IoT projects having failed. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, Chief IoTologist at Wipro, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology portfolios and business models to adopt and leverage IoT. He will delve in...
In his session at @ThingsExpo, Steve Wilkes, CTO and founder of Striim, will delve into four enterprise-scale, business-critical case studies where streaming analytics serves as the key to enabling real-time data integration and right-time insights in hybrid cloud, IoT, and fog computing environments. As part of this discussion, he will also present a demo based on its partnership with Fujitsu, highlighting their technologies in a healthcare IoT use-case. The demo showcases the tracking of patie...
DevOps and microservices are permeating software engineering teams broadly, whether these teams are in pure software shops but happen to run a business, such Uber and Airbnb, or in companies that rely heavily on software to run more traditional business, such as financial firms or high-end manufacturers. Microservices and DevOps have created software development and therefore business speed and agility benefits, but they have also created problems; specifically, they have created software securi...
In today's enterprise, digital transformation represents organizational change even more so than technology change, as customer preferences and behavior drive end-to-end transformation across lines of business as well as IT. To capitalize on the ubiquitous disruption driving this transformation, companies must be able to innovate at an increasingly rapid pace. Traditional approaches for driving innovation are now woefully inadequate for keeping up with the breadth of disruption and change facing...
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you...
Addteq is one of the top 10 Platinum Atlassian Experts who specialize in DevOps, custom and continuous integration, automation, plugin development, and consulting for midsize and global firms. Addteq firmly believes that automation is essential for successful software releases. Addteq centers its products and services around this fundamentally unique approach to delivering complete software release management solutions. With a combination of Addteq's services and our extensive list of partners,...
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Stratoscale, the software company developing the next generation data center operating system, exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016.Stratoscale is revolutionizing the data center with a zero-to-cloud-in-minutes solution. With Stratoscale’s hardware-agnostic, Software Defined Data Center (SDDC) solution to store everything, run anything and scale everywhere, IT is empowered to take control of their data ce...
Tricky charts and visually deceptive graphs often make a case for the impact IT performance has on business. The debate isn't around the obvious; of course, IT performance metrics like website load time influence business metrics such as conversions and revenue. Rather, this presentation will explore various data analysis concepts to understand how, and how not to, assert such correlations. In his session at 20th Cloud Expo, Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Sys...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...